After Searing Debate, FDA Clears Unproven Sarepta Drug
The U.S. Food and Drug Administration on Monday cleared a $300,000 drug from Sarepta Therapeutics for muscular dystrophy despite unproven benefits, capping an extraordinary review process that saw the agency's top...To view the full article, register now.
Already a subscriber? Click here to view full article